EC nod for merger of Mylan and Pfizer’s Upjohn division
The decision ensures that the merger between Mylan and Upjohn does not harm competition
Read Moreby Selina McKee | Apr 23, 2020 | News | 0
The decision ensures that the merger between Mylan and Upjohn does not harm competition
Read Moreby Selina McKee | Nov 27, 2018 | News | 0
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
Read Moreby Selina McKee | Nov 14, 2018 | News | 0
Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Read Moreby Selina McKee | Nov 14, 2018 | News | 0
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
Read Moreby Selina McKee | Jun 14, 2018 | News | 0
Mylan has announced that US regulators are going to reject its generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus.
Read Moreby Selina McKee | Jun 5, 2018 | News | 0
Mylan and Biocon’s Fulphila has become the first biosimilar of Amgen’s Neulasta to be approved by the US Food and Drug Administration.
Read Moreby Selina McKee | Mar 2, 2018 | News | 0
Mylan and Revance Therapeutics have unveiled plans to develop a biosimilar to Allergan’s neuromodulator Botox.
Read Moreby Selina McKee | Jan 24, 2018 | News | 0
Mylan has launched in the UK the first generic formulation of Teva’s multiple sclerosis blockbuster Copaxone, offering a potentially cheaper alternative for treatment of relapsing forms of the condition.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
